

STN Columbus

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:32:18 ON 18 FEB 2006

=> FILE REG

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 3.57 | 3.57 |

FILE 'REGISTRY' ENTERED AT 11:42:45 ON 18 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STN Columbus

STRUCTURE FILE UPDATES: 16 FEB 2006 HIGHEST RN 874442-49-6
DICTIONARY FILE UPDATES: 16 FEB 2006 HIGHEST RN 874442-49-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> Uploading C:\stnweb\Queries\10791578.str

L1 STRUCTURE uploaded

```
=> s ll
SAMPLE SEARCH INITIATED 11:42:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      3714 TO ITERATE
```

53.9% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTED ITERATIONS: 70626 TO 77934
PROJECTED ANSWERS: 1 TO 118

L2 1 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 11:43:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      75735 TO ITERATE
```

100.0% PROCESSED 75735 ITERATIONS 198 ANSWERS
SEARCH TIME: 00.00.02

L3 198 SEA SSS FUL L1

STN Columbus

FULL ESTIMATED COST

166.94 170.51

FILE 'CAPLUS' ENTERED AT 11:43:17 ON 18 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Feb 2006 VOL 144 ISS 9
FILE LAST UPDATED: 17 Feb 2006 (20060217/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S 13
L4 7 L3

=> D 14 1-7 bib abs fhitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

Full Text

AN 2005:980814 CAPLUS

DN 143:431985

TI Privileged structure-based ligands for melanocortin receptors-tetrahydroquinolines, indoles, and aminotetralines

AU Fisher, Matthew J.; Backer, Ryan T.; Husain, Saba; Hsiung, Hansen M.; Mullaney, Jeffrey T.; O'Brian, Thomas P.; Ornstein, Paul L.; Rothhaar, Roger R.; Zgombick, John M.; Briner, Karin

CS Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46258, USA


SO Bioorganic Medicinal Chemistry Letters (2005), 15(20), 4459-4462
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

GI



AB Substitution of the aryl sulfonamide moiety contained in MC4 agonist (I) with bicyclic heterocycles and aminotetralines produced compds. with MC4 activity. The heterocycles represent alternative privileged structures to that contained in I. Compds. in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist I, while those with an exocyclic polar group afforded activity competitive with I.

IT 444619-63-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(privileged structure-based ligands for melanocortin receptors-tetrahydroquinolines, indoles, and aminotetralines)

RN 444619-63-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-[1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-isoquinolinyl]-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
[Full Text](#)

STN Columbus


AN 2004:1080868 CAPLUS
 DN 142:38280
 TI Preparation of piperazinyltetrahydroquinolines as serotonin 5-HT1B antagonists.

IN Lowe, John Adams, III
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2004108682 | A2 | 20041216 | WO 2004-IB1855 | 20040601 |
| WO 2004108682 | A3 | 20050428 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| US 2004254193 | A1 | 20041216 | US 2004-852726 | 20040524 |
| PRAI US 2003-477559P | P | 20030611 | | |
| OS MARPAT 142:38280 | | | | |
| GI | | | | |



AB Title compds. [I; X = CH₂, CH₂CH₂, CO, COCH₂, OCH₂, OCH₂CH₂; Y = alkyl, (substituted) Ph, naphthyl, heteroaryl], were prep'd. Thus, 8-bromoisoquinoline and PhCH₂BVr were refluxed together for 6 h in EtOH to give an oil which was stirred with NaBH₃CN in MeOH for 5 days to give 59% N-benzyl-8-bromotetrahydroisoquinoline. This was heated with N-methylpiperazine, Pd(OAc)₂, BINAP, and NaOCMe₃ in PhMe at 120° for 16 h to give 84% N-benzyl-8-(4-methylpiperazin-1-yl)tetrahydroisoquinoline. The latter was hydrogenolyzed followed by acylation with 4-chlorophenylacetic acid in the presence of EDAC and N-hydroxybenzotriazole in CH₂Cl₂ at room temp. to give N-(4-chlorophenylacetyl)-8-(4-methylpiperazin-1-yl)tetrahydroisoquinoline. I showed 5-HT1B receptor affinity with IC₅₀ < 0.60 μM.


IT 807330-10-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compd.; prepn. of piperazinyltetrahydroquinolines as serotonin 5-HT1B antagonists)

STN Columbus

RN 807330-10-5 CAPLUS

CN Isoquinoline, 2-[(4-chlorophenyl)acetyl]-1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

Full Text

AN 2004:756620 CAPLUS

DN 141:277505

TI Preparation of 2,5- and 2,6-substituted tetrahydroisoquinolines as 5-HT6 modulators, in particular selective 5-HT6 antagonists, for treating CNS disorders

IN Putman, David George

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2



AppS

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004078176 | A1 | 20040916 | WO 2004-EP1751 | 20040223 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2517146 | AA | 20040916 | CA 2004-2517146 | 20040223 |
| | EP 1601358 | A1 | 20051207 | EP 2004-713547 | 20040223 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | US 2004180874 | A1 | 20040916 | US 2004-791578 | 20040302 |
| PRAI | US 2003-451516P | P | 20030303 | | |
| | WO 2004-EP1751 | W | 20040223 | | |
| OS | MARPAT 141:277505 | | | | |
| GI | | | | | |



AB Title compds. I [wherein n = 0-3; X = CH₂ and derivs.; C(:O); Y = SO₂ when X = CH₂ and derivs., and Y = (CH₂)_p and derivs. when X = C(:O); p = 1-3; each R₁ = independently halo, hetero/halo/alkyl, OH and derivs., NO₂, CN, S(O)_qH and derivs., NH₂ and derivs., CONH₂ and derivs., SO₂NH₂ and derivs., etc.; q = 0-2; R₂ = hetero/aryl, cycloalkyl; R₃, R₄ = independently H, alkyl; R₅ = 5- to 7-membered nitrogen-contg. heterocycle attached to the 5 or 6 position of the isoquinoline ring; their pharmaceutically acceptable salts or prodrugs] were prep'd. as 5-HT₆ modulators for the treatment of central nervous system (CNS) disorders. Claimed are 5-HT₆ agonists useful for treating CNS diseases. A 5-step synthesis is given for tetrahydroisoquinoline salt II•TFA. In an in vitro radioligand binding study, I were found selective 5-HT₆ antagonists. Selected I showed high affinity for 5-HT₆ receptor with pKi values in the range 9.28-10.37 in a radioligand assay. Thus, I are useful in treating mental disorders.


IT 757966-35-1P, 2-Benzenesulfonyl-5-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT₆ antagonist; prepn. of tetrahydroisoquinolines as 5-HT₆ modulators for treating CNS disorders)

RN 757966-35-1 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-5-(4-methyl-1-piperazinyl)-2-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



STN Columbus

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

Full Text

AN 2003:356439 CAPLUS

DN 138:368779

TI Preparation of isoquinolines as 5-HT antagonists for treatment of psychiatric disorders

IN Angst, Christof; Haeberlein, Markus; Hill, Daniel; Jacobs, Robert; Moore, Gary; Pierson, Edward; Shenvi, Ashokkumar Bhikkappa

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 139 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|-------------------|------|----------|-----------------|----------|
| PI | WO 2003037887 | A1 | 20030508 | WO 2002-SE1988 | 20021101 |
| | WO 2003037887 | C1 | 20050317 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | CA 2464342 | AA | 20030508 | CA 2002-2464342 | 20021101 |
| | EP 1451172 | A1 | 20040901 | EP 2002-780244 | 20021101 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| | BR 2002013778 | A | 20041109 | BR 2002-13778 | 20021101 |
| | JP 2005516896 | T2 | 20050609 | JP 2003-540168 | 20021101 |
| | ZA 2004003240 | A | 20050407 | ZA 2004-3240 | 20040429 |
| | NO 2004002154 | A | 20040729 | NO 2004-2154 | 20040525 |
| PRAI | SE 2001-3644 | A | 20011101 | | |
| | WO 2002-SE1988 | W | 20021101 | | |
| OS | MARPAT 138:368779 | | | | |
| | GI | | | | |




AB Title compds. I [wherein W = CO, CONRa, NRaCO, CO(CH₂)_nNRaCO, CSNRa, COCH₂O, SO₂NRa, NRaSO₂, CH₂NRa, COCH₂, CH₂CO, or 5-membered heterocycl; X = (un)substituted aryl or heterocycl; Y = bond, CH₂, O, S, SO, CO, SO₂, NRb, or NRbSO₂; Z = Rb, CO₂Ra, CON(Ra)₂, NHRb, alkyl-N(Ra)₂, SO₂Rc, or (un)substituted aryl(alkyl) or heterocycl; R1 = halo, alkyl, ORa, SORa, N(Ra)₂, or CN; R2 = aryl or heterocycl(carbonyl); Ra = H or (un)substituted alkyl; Rb = H, alkyl(sulfanyl), alkanoyl, aryl(alkyl), or arylalkoxyalkyl; Rc = alkyl, aryl, or heterocycl; m = 0 or 1; n = 0-4; p = 0-2;] were prep'd. as 5-HT1B and 5-HT1D antagonists (no data). For example, O-methylation of 5-hydroxyisoquinoline using NaOBu-t and PhMe₃NCl in DMF (85%), followed by bromination with bromine in AcOH gave 5-methoxy-8-bromoisoquinoline (47%). Substitution with N-methylpiperazine using NaOBu-t, BINAP, and tris(dibenzylideneacetone)dipalladium in PhMe and subsequent redn. with NaCNBH₃ and BF₃•Et₂O in MeOH gave 5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline. Coupling of 4-(bromomethyl)phenylacetic acid with morpholine in the presence of K₂CO₃ in MeCN provided 4-(morpholinomethyl)phenylacetic acid. Amidation of the tetrahydroisoquinoline with the phenylacetic acid in DMF afforded II. I are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders (no data). The compds. may also be useful in the treatment of gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm, and sexual dysfunction (no data).

IT 521313-56-4P, 1-[5-Benzyl-8-(4-methylpiperazin-1-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-2-(4-isopropylphenyl)ethanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (5-HT antagonist; prepn. of isoquinolines as 5-HT1B and 5-HT1D antagonists for treatment of psychiatric disorders)

RN 521313-56-4 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-(1-methylethyl)phenyl]acetyl]-8-(4-methyl-1-piperazinyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

Full Text

AN 2002:575065 CAPLUS

DN 137:140776

TI Preparation of piperidinyl and piperazinyl amino acid derivatives as melanocortin receptor agonists

IN Backer, Ryan Thomas; Briner, Karin; Doecke, Christopher William; Fisher, Matthew Joseph; Kuklish, Steven Lee; Mancuso, Vincent; Martinelli, Michael John; Mullaney, Jeffrey Thomas; Xie, Chaoyu

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 263 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002059107 | A1 | 20020801 | WO 2002-US516 | 20020123 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2433025 | AA | 20020801 | CA 2002-2433025 | 20020123 |
| | EP 1368339 | A1 | 20031210 | EP 2002-701923 | 20020123 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004521117 | T2 | 20040715 | JP 2002-559409 | 20020123 |
| | US 2004058936 | A1 | 20040325 | US 2003-466249 | 20030711 |
| PRAI | US 2001-263595P | P | 20010123 | | |
| | WO 2002-US516 | W | 20020123 | | |
| OS | CASREACT 137:140776; MARPAT 137:140776 | | | | |
| GI | | | | | |



AB The invention relates to melanocortin receptor (MC-R) agonists I [G = CR1 or N; LL1 = H2 or oxo; T = isoquinolinyl or tetrahydro deriv., isoindolinyl, or piperazinyl; n = 0-8; R = H, OH, CN, NO2, halo, alkyl, acyl, etc.; R1 = H, alkyl, alkylcarbamoyl, (D)phenyl, (D)cycloalkyl, or oxo (unless amide is formed); p = 0-4; CR2CR2 is a 5- or 6-membered carbocycle optionally substituted by 1-3 groups R; R3 = (un)substituted aryl or thienyl; R4 = H, alkyl, acyl, cycloalkyl, or alkoxyalkyl], or their pharmaceutically-acceptable salts or stereoisomers, which are useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction. Compds. I comprise three domains, i.e., a piperidino or piperazinyl fragment, an amino acid, and a radical CLL1(CH2)n-T. Thus, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [1-(4-chlorobenzyl)-2-[4-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]piperazin-1-yl]-2-oxoethyl]amide (claimed compd.) was prep'd. via acylation of the piperazine moiety.

IT 444619-63-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444619-63-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-[1,2,3,4-tetrahydro-2-(phenylsulfonyl)-8-isooquinolinyl]-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

STN Columbus

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

Full Text

AN 2000:742072 CAPLUS

DN 133:309907

TI Preparation of nitrogen-containing heterocyclic compounds and benzamide compounds as hypolipidemics and antiarteriosclerotics

IN Ohkura, Naoto; Hiraiwa, Yukiko; Matsushima, Tetsuya; Sasaki, Kazue; Yamamoto, Takehiro; Shiotani, Masaharu; Suzuki, Shigeki; Nakatani, Yuuko; Kuroda, Chizuko; Nagasawa, Mieko; Katano, Kiyoaki

PA Meiji Seika Kaisha, Ltd., Japan

SO PCT Int. Appl., 284 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000061556 | A1 | 20001019 | WO 2000-JP2329 | 20000410 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2369103 | AA | 20001019 | CA 2000-2369103 | 20000410 |
| | BR 2000009650 | A | 20020102 | BR 2000-9650 | 20000410 |
| | EP 1180514 | A1 | 20020220 | EP 2000-915465 | 20000410 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AU 779550 | B2 | 20050127 | AU 2000-36759 | 20000410 |
| | US 6777414 | B1 | 20040817 | US 2001-958296 | 20011005 |
| | US 2004224959 | A1 | 20041111 | US 2004-868006 | 20040616 |
| PRAI | JP 1999-102559 | A | 19990409 | | |
| | JP 1999-118490 | A | 19990426 | | |
| | JP 1999-119043 | A | 19990427 | | |
| | WO 2000-JP2329 | W | 20000410 | | |
| | US 2001-958296 | A3 | 20011005 | | |
| OS | MARPAT 133:309907 | | | | |
| | GI | | | | |





AB The title compds. [I; R1 and R2 represent each (un)substituted C1-6 alkyl or alkoxy, C3-8 cycloalkyl, Ph, C2-6 alkenyl or alkynyl, 5- or 6-membered ring (un)satd. heterocyclyl; R3 and R4 represent each hydrogen, (un)substituted C1-6 alkyl, halo, OH, cyano, C2-5 alkoxy carbonyl, C1-6 alkoxy, or CO₂H ; or R2 and R3 may be bonded to each other to form (CH₂)_m, N:CH, CH:N, or (C1-6 alkyl)-C:N; wherein m is 1 or 2; A, D, E and G represent each C, or one of A, D, E and G represents N and the remainders represent C; Q represents N or C; Y represents a group represented by general formula Q1 (wherein X represents hydrogen, CONR₅R₆, etc.; R₈ represents nil or a bond, O, etc.; and R₉ and R₁₀ represent each hydrogen, alkyl, etc.); and Z represents (CH₂)_n, O(CH₂)_i, or CONH(CH₂)_i; wherein n is 0-6; i is 1-6] are prep'd. These compds. have an effect of inhibiting the biosynthesis of triglycerides in the liver and an effect of inhibiting the secretion of apolipoprotein B-contg. lipoproteins from the liver (the latter effect being particularly excellent), without showing the side effect of fat accumulation in the liver, and are useful in treating and preventing hyperlipemia, arteriosclerotic diseases, and pancreatitis. Thus, to a soln. of 2-benzyl-7-[4-[4-[9-(2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]butyl]piperazin-1-yl]-3,4-dihydro-2H-isooquinolin-1-one in PhMe were added NaOH, K₂CO₃, tetrabutylammonium hydrogen sulfate, and allyl bromide and the resulting mixt. was stirred at 60° overnight to give title compd. (II). II in vitro inhibited the secretion of apolipoprotein B by 89% and the biosynthesis of triglycerides by 89% in HepG2 cells. Tablet and capsule formulations were also described.

IT 301666-52-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prep'n. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)

RN 301666-52-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isooquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
Full Text

AN 1998:793126 CAPLUS

DN 130:52434

TI Prepn. of nitrogenous heterocyclic compounds as hyperlipemia remedies

IN Ohkura, Naoto; Tsuruoka, Takashi; Usui, Takayuki; Hiraiwa, Yukiko; Matsushima, Tetsuya; Shiotani, Masaharu; Niizato, Tetsutaro; Nakatani, Yuuko; Suzuki, Shigeki; Kuroda, Chidsuko; Katano, Kiyoaki

PA Meiji Seika Kaisha, Ltd., Japan; et al.

SO PCT Int. Appl., 194 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9854135 | A1 | 19981203 | WO 1998-JP2411 | 19980601 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2291630 | AA | 19981203 | CA 1998-2291630 | 19980601 |
| | AU 9875482 | A1 | 19981230 | AU 1998-75482 | 19980601 |
| | EP 999208 | A1 | 20000510 | EP 1998-923066 | 19980601 |
| | R: DE, ES, FR, GB, IT | | | | |
| | US 6417362 | B1 | 20020709 | US 1999-424708 | 19991130 |
| | US 2002156276 | A1 | 20021024 | US 2002-127491 | 20020423 |
| | US 6583144 | B2 | 20030624 | | |
| PRAI | JP 1997-141410 | A | 19970530 | | |
| | WO 1998-JP2411 | W | 19980601 | | |
| | US 1999-424708 | A3 | 19991130 | | |
| OS | MARPAT 130:52434 | | | | |
| GI | | | | | |




AB The title compds. [I; A = CR₁R₂(CH₂)_i; (wherein R₁ and R₂ each represents hydrogen or alkyl, i = 0-1), CH:CH, OCH₂, or S(O)_jCH₂ (wherein j = 0-2); B = hydrogen or halogen; X = CR₃R₄R₅, NR₆R₇, (CH₂CH:C(CH₃)CH₂)_pCH₂CH:C(CH₃)₂, alkyl, cycloalkyl, Ph, cinnamyl, or heteroaryl; Y = (CH₂)_q, CH:CH, NR₈, oxygen, or a bond; Z = carbonyl or a bond; K = alkylene or a bond; L = CH:CH or a bond; and M = hydrogen, alkyl, cycloalkyl, Ph, heterocycle, biphenyl, or diphenylmethyl; p = 0-2; q = 1-6; R₃-R₅ = hydrogen, phenyl; R₆-R₇ = hydrogen, Ph, benzyl; R₈ = hydrogen, C₁₋₆ alkyl] are prep'd. I inhibit the biosynthesis of triglycerides in the liver and also inhibit the secretion of lipoproteins contg. apolipoprotein B from the liver. I are hence useful for the prevention/treatment of hyperlipemia (esp. hyper-VLDL-emia) and diseases caused thereby, such as arteriosclerotic diseases, e.g., myocardial infarct, and pancreatitis. Thus, title compd. (II) was prep'd. by multi-step reactions and showed 56% and 90% inhibitory activity for apolipoprotein B and triglycerides. A formulation contg. I was also presented.

IT 217492-19-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogenous heterocyclic compds. as hyperlipemia remedies)

RN 217492-19-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|------------------|
| 38.07 | 208.58 |

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|------------------|
|---------------------|------------------|

STN Columbus

CA SUBSCRIBER PRICE

-5.25 -5.25

FILE 'CAOLD' ENTERED AT 11:46:07 ON 18 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13
L5 0 L3

| | | | |
|--|------------------|---------------|--|
| => file reg | | | |
| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION | |
| FULL ESTIMATED COST | 0.44 | 209.02 | |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION | |
| CA SUBSCRIBER PRICE | 0.00 | -5.25 | |

FILE 'REGISTRY' ENTERED AT 11:46:16 ON 18 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 FEB 2006 HIGHEST RN 874442-49-6
DICTIONARY FILE UPDATES: 16 FEB 2006 HIGHEST RN 874442-49-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

STN Columbus

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 11:32:18 ON 18 FEB 2006)

FILE 'REGISTRY' ENTERED AT 11:42:45 ON 18 FEB 2006
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 198 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 11:43:17 ON 18 FEB 2006
L4 7 S L3

FILE 'CAOLD' ENTERED AT 11:46:07 ON 18 FEB 2006
L5 0 S L3

FILE 'REGISTRY' ENTERED AT 11:46:16 ON 18 FEB 2006

=> save l3
ENTER NAME OR (END):ten791578/a
ANSWER SET L3 HAS BEEN SAVED AS 'TEN791578/A'

=>



chain nodes :

19 20 22 24 25 26 29 30 31 32 36

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

7-19 8-20 9-36 13-22 24-25 25-26 29-30 29-31 29-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16
12-13 13-14 14-15 15-16

exact/norm bonds :

5-7 6-10 7-8 7-19 8-9 8-20 9-10 9-36 11-12 11-16 12-13 13-14
13-22 14-15 15-16 25-26 29-30 29-31 29-32

exact bonds :

24-25

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 11 :

G2:C,H

G3:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
19:CLASS 20:CLASS 22:CLASS 24:CLASS 25:CLASS 26:Atom 29:CLASS
30:CLASS

31:CLASS 32:Atom 36:CLASS